Related Experiment Video

Updated: Jul 5, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Targeting growth factors in lung cancer

Philip S Hodkinson1, Alison Mackinnon, Tariq Sethi

  • 1University of Edinburgh, MRC Centre for Inflammation Research, Queen's Institute of Medical Research, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, UK.

Chest
|May 8, 2008
PubMed

Insights

Targeting growth factor signaling offers a promising new approach for lung cancer therapy. Inhibitors targeting these pathways are now used in advanced lung cancer treatment, with ongoing research to enhance their effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Translational Research

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • Current treatments like surgery, chemotherapy, and radiotherapy offer limited improvements in long-term survival.
  • Novel therapeutic strategies targeting specific molecular pathways are urgently needed.

Purpose of the Study:

  • To review the role of growth factor signaling in lung cancer.
  • To discuss the development and clinical application of growth factor inhibitors.
  • To explore future research directions for improving targeted lung cancer therapy.

Main Methods:

  • Review of preclinical studies on extracellular growth factors in lung cancer.
  • Analysis of molecular components of growth factor-signaling cascades.
  • Evaluation of clinical trials involving selective growth factor inhibitors.

Main Results:

  • Extracellular growth factors significantly influence lung cancer cell proliferation, metastasis, and treatment resistance.
  • Targeted growth factor inhibitors have shown efficacy and are incorporated into advanced lung cancer treatment regimens.
  • Ongoing research aims to optimize the effectiveness of these targeted therapies.

Conclusions:

  • Growth factor signaling pathways represent a critical therapeutic target in lung cancer.
  • Selective growth factor inhibitors are a valuable component of modern lung cancer treatment.
  • Further research is essential to refine and improve growth factor-targeted therapies for better patient outcomes.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...